Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia

References

• Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker B J, Larson R A, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108: 1478–1484
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, Allan N C, Baccarani M, Kluin-Nelemans J C, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858
   Google Scholar
• Sokal J E, Cox E B, Baccarani M, Tura S, Gomez G A, Robertson J E, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820
   PubMed Web of Science ®Google Scholar
• Bullinger L, Dohner K, Bair E, Frohling S, Schlenk R F, Tibshirani R, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605–1616
   PubMed Web of Science ®Google Scholar
• Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169
   PubMed Web of Science ®Google Scholar
• Michor F, Hughes T P, Iwasa Y, Branford S, Shah N P, Sawyers C L, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267–1270
   PubMed Web of Science ®Google Scholar
• Crossman L C, Mori M, Hsieh Y C, Lange T, Paschka P, Harrington C A, et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 2005; 90: 459–464
   PubMed Web of Science ®Google Scholar
• Yong A S, Szydlo R M, Goldman J M, Apperley J F, Melo J V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006; 107: 205–212
   PubMed Web of Science ®Google Scholar
• Radich J P, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794–2799
   PubMed Web of Science ®Google Scholar
• Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006; 20: 1400–1407
   PubMed Web of Science ®Google Scholar
• McLean L A, Gathmann I, Capdeville R, Polymeropoulos M H, Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 2004; 10: 155–165
   PubMed Web of Science ®Google Scholar
• Villuendas R, Steegmann J L, Pollan M, Tracey L, Granda A, Fernandez-Ruiz E, et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 2006; 20: 1047–1054
   PubMed Web of Science ®Google Scholar
• Tipping A J, Deininger M W, Goldman J M, Melo J V. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 2003; 31: 1073–1080
   PubMed Web of Science ®Google Scholar
• Hagberg A, Olsson-Stromberg U, Wickenberg-Bolin U, Goransson H, Isaksson A, Bengtsson M, et al. Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients. Leuk Res 2007; 31: 931–938
   PubMed Web of Science ®Google Scholar
• Nowicki M O, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene 2003; 22: 3952–3963
   PubMed Web of Science ®Google Scholar
• Ohmine K, Ota J, Ueda M, Ueno S, Yoshida K, Yamashita Y, et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene 2001; 20: 8249–8257
   PubMed Web of Science ®Google Scholar
• Zheng C, Li L, Haak M, Brors B, Frank O, Giehl M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006; 20: 1028–1034
   PubMed Web of Science ®Google Scholar
• Kronenwett R, Butterweck U, Steidl U, Kliszewski S, Neumann F, Bork S, et al. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene 2005; 24: 5313–5324
   PubMed Web of Science ®Google Scholar
• Diaz-Blanco E, Bruns I, Neumann F, Fischer J C, Graef T, Rosskopf M, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 2007; 21: 494–504
   PubMed Web of Science ®Google Scholar
• Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genetics Cytogenetics 2001; 128: 114–119
   PubMed Web of Science ®Google Scholar